Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBL 514

Next Previous
X
Search
Drug Profile

CBL 514

Alternative Names: CBL-514

Latest Information Update: 16 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Caliway Biopharmaceuticals Australia
  • Class Obesity therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Apoptosis stimulants; Lipolysis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adiposis dolorosa
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adiposis dolorosa; Cellulite; Obesity; Subcutaneous fat disorders

Most Recent Events

  • 11 Dec 2024 Efficacy and adverse events data from phase-IIb trial in Subcutaneous fat disorders released by Caliway Biopharmaceuticals
  • 12 Nov 2024 CBL 514 receives Orphan Drug status for Adiposis dolorosa in European Union
  • 23 Oct 2024 Caliway Biopharmaceuticals announces intention to receive IND application approval for a phase III pivotal CBL-0301 trial from the US FDA and Health Canada for Subcutaneous fat disorders by 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top